UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

The Lancet (British edition), 2010-07, Vol.376 (9737), p.235-244

2010

Volltextzugriff (PDF)

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

The Lancet (British edition), 2010-07, Vol.376 (9737), p.245-251

2010

Volltextzugriff (PDF)

Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation

Journal of clinical oncology, 2015-01, Vol.33 (3), p.244-250

2015

Volltextzugriff (PDF)

Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II study

Investigational new drugs, 2013-10, Vol.31 (5), p.1345-1354

2013

Volltextzugriff (PDF)

Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy

Gynecologic oncology, 2016-02, Vol.140 (2), p.199-203

2016

Volltextzugriff (PDF)

MammaPrint and BluePrint comprehensively capture the cancer hallmarks in early‐stage breast cancer patients

Genes chromosomes & cancer, 2022-03, Vol.61 (3), p.148-160

2022

Volltextzugriff (PDF)

BluePrint breast cancer molecular subtyping recognizes single and dual subtype tumors with implications for therapeutic guidance

Breast cancer research and treatment, 2022-10, Vol.195 (3), p.263-274

2022

Volltextzugriff (PDF)

Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial

Journal of clinical oncology, 2024-10, Vol.42 (30), p.3561-3569

2024

Volltextzugriff (PDF)

Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition

Pharmacogenomics and personalized medicine, 2014-01, Vol.7 (default), p.307-316

Audeh, M William

2014

Volltextzugriff (PDF)

A breast cancer gene signature for indolent disease

Breast cancer research and treatment, 2017-07, Vol.164 (2), p.461-466

2017

Volltextzugriff (PDF)

Letting the genome out of the bottle

The New England journal of medicine, 2008-05, Vol.358 (20), p.2184

Audeh, M William

2008

Volltextzugriff (PDF)

Challenges to the development of new agents for molecularly defined patient subsets: lessons from BRCA1/2-associated breast cancer

Journal of clinical oncology, 2011-11, Vol.29 (32), p.4224-4226

2011

Volltextzugriff (PDF)

Breast Cancer Survivorship and Cardiovascular Disease: Emerging Approaches in Cardio-Oncology

Current treatment options in cardiovascular medicine, 2015-12, Vol.17 (12), p.60-60, Article 60

2015

Volltextzugriff (PDF)

Letting the Genome Out of the Bottle

The New England journal of medicine, 2008-05, Vol.358 (20), p.2184-2185

2008

Volltextzugriff (PDF)

Investigation of a genomic signature for transcription factor MAF gene amplification and lack of bisphosphonate benefit in early breast cancer

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.559-559

2022

Volltextzugriff (PDF)

FLEX, a real-world evidence full transcriptome study of 30,000 patients with early-stage breast cancer

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS621-TPS621

2023

Volltextzugriff (PDF)

Association of MammaPrint index and 3-year outcome of patients with HR+HER2- early-stage breast cancer treated with chemotherapy with or without anthracycline

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.511-511

2024

Volltextzugriff (PDF)

Identification of transcriptional changes with MammaPrint and BluePrint in early-stage breast cancer after neoadjuvant chemotherapy

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.585-585

2022

Volltextzugriff (PDF)

Impact of race on BluePrint genomic subtyping in HER2+ breast cancer

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.564-564

2023

Volltextzugriff (PDF)

Elucidating the immune active state of HR+HER2- MammaPrint High 2 early breast cancer

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.506-506

2024

Volltextzugriff (PDF)

Distribution of breast cancer molecular subtypes within receptor classifications: Lessons from the I-SPY2 Trial and FLEX Registry

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.592-592

2022

Volltextzugriff (PDF)

Defining transcriptomic profiles of early-stage mucinous breast cancers: A FLEX sub study

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.3134-3134

2022

Volltextzugriff (PDF)

Whole transcriptomic analysis of HR+ breast cancer in Black women classified as basal-type by BluePrint

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.517-517

2022

Volltextzugriff (PDF)

MammaPrint Index as a predictive biomarker for neoadjuvant chemotherapy response and outcome in patients with HR+HER2- breast cancer in NBRST

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.521-521

2023

Volltextzugriff (PDF)

Race and response to neoadjuvant chemotherapy according to MammaPrint risk

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.578-578

2019

Volltextzugriff (PDF)

1 – 25 von 74

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(71)
Mit Volltextzugriff
(67)

Publikationsform

Artikel
(74)

Sprache

Englisch
(74)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(23)
Science & Technology
(23)
Humans
(22)
Breast Cancer
(16)
Female
(16)
Oncology
(15)
Aged
(11)
Chemotherapy
(10)
Middle Aged
(10)
Adult
(9)
Tumors
(9)
Antineoplastic Agents - Therapeutic Use
(7)
Breast Neoplasms - Genetics
(7)
Cancer Therapies
(7)
Breast Neoplasms - Drug Therapy
(6)
Breast Neoplasms - Pathology
(6)
Genomics
(6)
Medicine
(6)
Medicine & Public Health
(6)
Mutation
(6)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation

Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II study

Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy

MammaPrint and BluePrint comprehensively capture the cancer hallmarks in early‐stage breast cancer patients

BluePrint breast cancer molecular subtyping recognizes single and dual subtype tumors with implications for therapeutic guidance

Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial

Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition

A breast cancer gene signature for indolent disease

Letting the genome out of the bottle

Challenges to the development of new agents for molecularly defined patient subsets: lessons from BRCA1/2-associated breast cancer

Breast Cancer Survivorship and Cardiovascular Disease: Emerging Approaches in Cardio-Oncology

Letting the Genome Out of the Bottle

Investigation of a genomic signature for transcription factor MAF gene amplification and lack of bisphosphonate benefit in early breast cancer

FLEX, a real-world evidence full transcriptome study of 30,000 patients with early-stage breast cancer

Association of MammaPrint index and 3-year outcome of patients with HR+HER2- early-stage breast cancer treated with chemotherapy with or without anthracycline

Identification of transcriptional changes with MammaPrint and BluePrint in early-stage breast cancer after neoadjuvant chemotherapy

Impact of race on BluePrint genomic subtyping in HER2+ breast cancer

Elucidating the immune active state of HR+HER2- MammaPrint High 2 early breast cancer

Distribution of breast cancer molecular subtypes within receptor classifications: Lessons from the I-SPY2 Trial and FLEX Registry

Defining transcriptomic profiles of early-stage mucinous breast cancers: A FLEX sub study

Whole transcriptomic analysis of HR+ breast cancer in Black women classified as basal-type by BluePrint

MammaPrint Index as a predictive biomarker for neoadjuvant chemotherapy response and outcome in patients with HR+HER2- breast cancer in NBRST

Race and response to neoadjuvant chemotherapy according to MammaPrint risk

Suchergebnisse filtern